Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15650145 | 0.81 | GFER (0.49) | — | |
| SCHEMBL29518820 | 0.80 | DEGS1 (0.54) | AKR1C3 | |
| SCHEMBL4703338 | 0.79 | NOTUM (0.50) | — | |
| SCHEMBL2556203 | 0.78 | TRIM24 (0.53) | — | |
| SCHEMBL4500240 | 0.77 | GPR119 (0.58) | GPR119AKR1C3CTSBCTSSCTSK | |
| SCHEMBL9983648 | 0.77 | MAPT (0.51) | — | |
| SCHEMBL3131722 | 0.77 | ITGB3 (0.49) | F10 | |
| SCHEMBL29518869 | 0.76 | NOTUM (0.55) | AKR1C3 | |
| SCHEMBL28849550 | 0.76 | GPR119 (0.60) | GPR119AKR1C3 | |
| SCHEMBL3640235 | 0.75 | FFAR1 (0.44) | CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572683-B1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| US-20060069120-A1 | Novel piperidine derivaties as modulators of chemokine receptor ccr5 | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | US | disclosed |
| EP-1572683-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056808-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069120-A1 | Novel piperidine derivaties as modulators of chemokine receptor ccr5 | CCR5, CCR2, CXCR4 | GPR119 103/4885AKR1C3 695/4885CTSB 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.